Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

DBP International AB: participate in semi-final of EIT Health Catapult 2020

Double Bond Pharmaceutical International AB (publ) (“Double Bond Pharmaceutical” eller “DBP”) was selected to pitch in the EIT Health Catapult semifinals in the biotech sector. The CEO Igor Lokot will present the company on Wednesday, October 21 at 10:45. Register for free to attend this year’s virtual pitch:  https://www.europeanhealthcatapult.eu/register-for-semifinals. “Double Bond Pharmaceutical provides unique investment opportunity: our ambitious team made a huge work in the development of SI-053 as a game-changer for treatment of malignancies in the brain; now I need to

DBP International AB: the SI-053 efficacy was successfully proven in in vivo study in mice

Double Bond Pharmaceutical International AB (publ) (“DBP”, “Double Bond” or “Double Bond Pharmaceutical”) reports today that the in vivo proof-of-concept study of SI-053 was successfully finished.  The in vivo study of the efficacy of SI-053, Double Bond’s front-line product for local treatment of primary malignancies in the brain, was designed and set up in accordance with recommendations from the European Agency of Medicines (EMA). It consisted of using an immunodeficient nude mouse with an injection of human glioblastoma cells to mimic the brain tumor in a subcutaneous model. The

DBP International AB: US patent for Temodex / SI-053 is granted

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, October 05, 2020, received information on granting a US patent application concerning the company's front-line product Temodex / SI-053. Patent approval provides protection for the technology and the product in USA at least until 2036. "This is a very important milestone in the development of SI-053 as USA is the most important  market where we plan to expand the global commercialization of the product," comments Igor Lokot, CEO of DBP. - We also have other applications pending

Double Bond Pharmaceutical concludes Key Opinion Leader (KOL) meeting, an important milestone for SI-053 Phase 1 clinical study

Uppsala, Sweden, 28 September 2020 - DBP has recently concluded KOL meeting with Professor Dr. Manfred Westphal (Department of neurosurgery, University Hospital Hamburg, Germany) and Professor Dr. Clemens M. F. Dirven (Department of Neurosurgery Erasmus Medical Center, The Netherlands), which has resulted in fine-tuning the Phase 1 clinical plan. This Phase 1 open-label dose escalation study is scheduled to begin in the first half of 2021. The aim of this study is to estimate the maximum tolerated dose (MTD) and safety of SI-053, when used as an add-on to standard of care in adult patients

DBP International AB: the subsidiary FarmPharma receives a grant of SEK 300,000

FarmPharma AB (publ), which is a subsidiary of Double Bond Pharmaceutical International AB (publ), have been granted SEK 300,000 by Vinnova in the call “Innovative Startups step 1”. The grant will support ongoing collaboration with Karolinska Institute for the production of starting materials for the company's drug candidate InterferOX. More about collaboration with Karolinska Institutet: https://mb.cision.com/Main/12720/2985377/1157822.pdf More about Vinnova: www.vinnova.se More about FarmPharma: FarmPharma AB (publ) is a subsidiary of Double Bond Pharmaceutical International AB (

DBP International AB: Joint Venture agreement with Shijiazhuang Yuanjia Biotechnology for Temodex in China

Double Bond Pharmaceutical International AB (publ) via it's subsidiary Double Bond Pharmaceutical AB ("DBP", org. No. 556959-2982) has today signed an agreement with Shijiazhuang Yuanjia Biotechnology Co., Ltd  via it's subsidiary Shijiazhuang Yuanta Biotechnology Co., Ltd ("SYB") for setting up a joint venture in China for commercialization of Temodex in the Chinese market. Under the terms of the agreement DBP grants to the joint venture exclusive rights for the product for 25% of shares of the joint venture as well as €0.5 million of milestones payment conditioned by formal market

DBP International AB: European patent for Temodex / SI-053 is granted

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, February 20, 2020, received information on granting a European patent application concerning the company's front-line product Temodex / SI-053 . Patent approval provides protection for the technology and the product in 26 European Patent Organization (EPO) countries at least until 2036. "This is a very important milestone in the development of SI-053 as Europe is an important regulated market where we plan to expand the global commercialization of the product," comments Igor

FarmPharma signs agreement with Karolinska Institutet

Today FarmPharma AB, the subsidiary of Double Bond Pharmaceutical AB, signed a collaboration agreement with Karolinska Institutet (Department of Medicine, Solna) to conduct a project of producing start material for FarmPharma products. The work is estimated to start immediately. The goal of the project is the large-scale testing of the production of InterferOX parts and the company’s other products in order to facilitate the transition to GMP production. “We are happy to be able to collaborate with world’s class researchers to fuel the development of PharmPharma’s products”, comments

Double Bond Pharmaceutical is a distributor of Inofer in Russia and Belarus

Last year, Double Bond Pharmaceutical and Laboratoire XO signed a distribution agreement for Inofer in Sweden, Norway, Denmark and Finland. Now Double Bond Pharmaceutical has the distribution rights for Russia and Belarus as well. Inofer is an iron supplement consisting of ferrous succinate which is a chemical iron form known to be more readily absorbed into the body of people with impaired iron uptake. According to WHO, "iron deficiency is the most common and widespread nutritional disorder in the world". Inofer is registered in France. The results of DBP's clinical trial of Inofer showed

Double Bond Pharmaceutical is seeking a patent for the use of iron succinate

Double Bond Pharmaceutical has filed a Swedish patent application to protect the use of iron succinate for certain indications. Earlier this year, a clinical study, a collaboration between Double Bond Pharmaceutical AB and Skellefteå University, showed that Inofer (iron succinate) significantly improves iron uptake, iron saturation and iron stores in patients with heart failure and iron deficiency. DBP’s subsidiary Drugsson AB, has the distribution right for Inofer (iron succinate) in Sweden, Norway, Denmark and Finland. "We are very pleased that the Inofer study, according to the

Clinical trial results indicate that Inofer markedly and significantly improved iron uptake, iron saturation and iron stores in patients with heart failure and iron deficiency

Double Bond Pharmaceutical International AB presents the results from a study evaluating Inofer – a medical product against iron deficiency – in patients with heart failure and iron deficiency without having anemia. Current knowledge recommends iron treatment to be given intravenously, as patients with heart failure have so far been regarded to have an insufficient uptake of oral iron treatment. In this pilot study, patients who received oral Inofer (iron succinate) had a markedly and significantly improved iron uptake, with improved iron saturation and iron stores.Iron deficiency occurs in

Euroresearch's and Zoono's products are now in Drugsson's warehouse

Double Bond Pharmaceutical's subsidiary Drugsson AB, distributor of Biopad, Biospray and a number of Biocide products (from Zoono) in the Nordic market, has received its deliveries of all products to Sweden. The products will be stored in stock. Biopad, Biospray is manufactured in Italy. The biocidal products are manufactured in New Zealand and imported via the UK. These are under registration in Sweden and will be available for the Swedish market shortly. “We are pleased that the products will be on sale shortly,” comments by Igor Lokot, CEO of Double Bond Pharmaceutical and Drugsson AB,

Double Bond Pharmaceutical receives Eurasian patent for the BeloGal® platform

Double Bond Pharmaceuticals patent application for organ-specific administration of hydrophilic cancer drug to the liver which forms the basis for the BeloGal® technology platform has been granted by the Eurasian Patent Organization (EAPO). Patent approval provides protection for the technology platform BeloGal® and products on the territory of 8 member states at least through 2035. "It is the company's second granted patent and we are very pleased that it concerns the geographically largest market. With the patent, we have achieved an important interim goal for the commercialization of

Double Bond Pharmaceutical joins hands with SMS-oncology for clinical development of SI-053

Uppsala, Sweden and Schiphol, the Netherlands (09 Oct 2019) - Double Bond Pharmaceutical AS (“DBP”) announces today that Specialized Medical Services-oncology BV ("SMS-oncology") has been chosen for providing consultancy services to support the transition of their lead candidate, SI-053 from the preclinical phase to the clinical phase. DBP’s strategy is to develop new medicines, thereby combining already known efficient approaches with their innovative first-in-class technologies to provide new therapeutic possibilities for treatment of life-threatening diseases. Its lead compound SI-053

Double Bond Pharma signed a distribution agreement with Zoono

Double Bond Pharmaceutical (DBP) has signed an agreement with Zoono for the distribution of selected products in the Scandinavian market. The sale of these products will be handled by it’s subsidiary Drugsson AB. Zoono provides cost effective, polymer based, broad-spectrum antimicrobial protection. The products are effective against bacteria, viruses, fungi (mould), yeasts, pathogens incl. MRSA, E.Coli, H1N1, Listeria, TB, black mould, Norovirus etc. Drugsson will market the products to both consumers (self-care) and healthcare, which shows that the products have a broad market. "

Temodex/SI053 will be presented at international conferences in North and South America

Temodex and Double Bond Pharmaceutical’s drug candidate SI053 will be presented at "Joint Conference of the Society for Neuro-Oncology and the Society for CNS Interstitial Delivery of Therapeutics on Therapeutic Delivery to the CNS" at November 20-21th (Phoenix, Arizona) and at "VII Congreso Massin, Society of International Neurosurgeons ”November 21-23 (Cartagene, Colombia). "I am pleased that we will present the experience with the use of Temodex and our development plans regarding SI053 to world experts in neuro-oncology on both American continents", - comments CEO Igor Lokot More

BeloGal® platform is applicable for lung-targeted delivery of Meropenem

The first step of the biodistribution study of Belopenem in rats has been successfully completed. Double Bond Pharmaceutical combined the BeloGal®platform with the well-known antibiotic Meropenem, giving rise to two working Belopenem formulations. The recent study showed a superior lung-targeted delivery of Meropenem through the formulations, when compared to the standard intravenous Meropenem solution. The study is expected to be completed in December 2019 – January 2020. “I am very glad that we are able to validate the BeloGal®platform for lung-targeting of an additional API –

FarmPharma starts the project at Testa Center

FarmPharma AB, which is subsidiary to Double Bond Pharmaceutical AB, has today started the project at Testa Center as a part of cooperation agreement with GE Healthcare in Uppsala. As previously announced , FarmPharma has been granted financial means for this project within the framework of the "BioProcess Innovation Center" from Vinnova. The work is expected to last for one week in July and two weeks in August. The purpose of the project is to test the manufacturing procedure of InterferOX components on a

FarmPharma signs agreement with Testa Center

FarmPharma AB, which is subsidiary to Double Bond Pharmaceutical AB, has today signed a cooperation agreement with GE Healthcare to implement a project at Testa Center in Uppsala. As previously announced, FarmPharma has been granted financial means for this project within the framework of the "BioProcess Innovation Center" from Vinnova. The work is expected to start during the summer this year and last for three weeks. The purpose of the project is to test the manufacturing procedure of InterferOX components on a larger scale to facilitate the successful transition to industrial GMP

Clinical trial of Inofer: last patient out

All samples from patients included in the clinical study of the iron tablets Inofer have now been obtained. As earlier announced, a clinical trial of Inofer was approved by the Swedish Medical Products Agency and the National Ethical Committee June 20, 2018, and the study started on October 4 when the first patient received treatment with Inofer tablets. The study was conducted at Skellefteå Hospital and was led by the chief physician Kurt Boman, senior professor at Umeå University. Drugsson AB, which is the subsidiary of Double Bond Pharmaceutical (DBP), has the rights to distribute Inofer

FarmPharma receives funding from Vinnova

FarmPharma AB that is subsidiary to Double Bond Pharmaceutical Int. AB, has been funded with the amount of SEK 400,000 from Vinnova within the project ”BioProcess Innovation Center” to perform a project in collaboration with GE Healthcare and Testa Center in Uppsala. The total budget of the project is 800 000 SEK and the company will cover the other half of the costs according to the general rules of the grant. The project is expected to start during the summer this year and last for three weeks. The purpose of the project is to test the manufacturing procedure of InterferOX components on a

FarmPharma receives EU funding SME instrument Phase I

As previously announced, FarmPharma AB that is subsidiary to Double Bond Pharmaceutical Int. AB, has submitted an application to the European Commission for an SME instrument grant within the framework of the Horizon2020 program, where groundbreaking innovation projects with market-generating potential can be supported. The company funds alone to implement a more in-depth and up to date business plan for continued successful development of InterferOX. The project under the name InFarm has now been funded with the amount of SEK 500,000, which corresponds to the entire sought amount and is

DBP receives EU funding SME instrument Phase I

As previously announced, Double Bond Pharmaceutical has submitted an application to the European Commission for an SME instrument grant within the framework of the Horizon2020 program, where groundbreaking innovation projects with market-generating potential can be supported. The company funds alone to implement a more in-depth and up to date business plan for continued successful development of SI053. The project under the name TARGLIO has now been funded with the amount of SEK 500,000, which corresponds to the entire sought amount and is the ceiling for this type of grant. "I am glad

There are no items matching the current filter
There are no more items matching the current filter
Back to top